Soon, a 'needle-free' vaccine for STI Chlamydia

Washington D.C, Jul 20: World's first vaccine for an insidious sexually transmitted infection (STI) has come closer to reality in the form of a nose spray.

Researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster have developed the first widely protective vaccine against chlamydia, a common STI that is mostly asymptomatic but impacts 113 million people around the world each year and can result in infertility.

In a study, the team showed that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.

As most C. trachomatis infections are asymptomatic, chlamydia can often go untreated and lead to upper genital tract infections, pelvic inflammatory disease, and infertility. This is why the promise of a vaccine would be extremely beneficial, said co-author David Bulir.

"Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans," said Bulir, adding "Vaccination would be the best way to way to prevent a chlamydia infection and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections."

BD584 was able to reduce chlamydial shedding, a symptom of C. trachomatis, by 95 per cent. The antigen also decreased hydrosalpinx, another C. trachomatis symptom, which involves fallopian tubes being blocked with serous fluids, by 87.5 percent.

The results look very promising, said senior author James Mahony.

Co-author and McMaster PhD student, Steven Liang, explains, "not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma."

"The vaccine would be administered through the nose. This is easy and painless and does not require highly trained health professionals to administer, and that makes it an inexpensive solution for developing nations," he said.

The next step is more testing for effectiveness against different strains of Chlamydia and in different formulations. The study was funded by the Canadian Institutes for Health Research.